DNA methylation biomarker for prostate cancer shows promise for accurately determining patient risk

(Elsevier Health Sciences) Report in The Journal of Molecular Diagnostics describes a biomarker, PITX2 DNA methylation, which is capable of distinguishing cancerous tissue from non-cancerous tissue and predicting the risk of cancer recurrence using only small amounts of tissue obtained from core needle biopsies.